HIPRA marks the first year of its CDMO with a first strategic contract
HIPRA Biotech Services reaches key milestones in its first year of operations, including signing its first agreement in just nine months and advancing new collaboration opportunities with European biotech companies.
HIPRA Biotech Services, HIPRA’s CDMO unit focused on the development and manufacturing of biological products and vaccines, has completed its first year of operations with results exceeding initial expectations and very positive growth prospects. Launched in January 2025, the unit achieved a significant milestone by securing its first contract in just nine months, in a sector where commercial cycles typically extend up to 18 months.
The agreement includes the supply of a biological product for clinical studies with a European biotechnology company and adds to a pipeline of projects currently in advanced negotiation stages. This progress validates HIPRA Biotech Services’ value proposition, based on the combination of scientific, technical and industrial capabilities, along with an agile and flexible partnership model for its clients.
With more than 50,000 m² of operational facilities, HIPRA has a production capacity of 24,000 litres for microbial cultures and 2,000 litres for cell cultures, with expansion plans underway to reach 8,000 litres in the coming years. The company also has aseptic filling capacity of up to 90 million vials per year. In addition, the unit is supported by state-of-the-art R&D laboratories covering the entire lifecycle of biological development.
In the short term, HIPRA Biotech Services aims to consolidate its position as a strategic partner for innovative companies and contribute to Europe’s strategic autonomy, with the goal of becoming a global reference in the CDMO field.
